Sleep Apnea in Early to Mid-Stage Alzheimer's Disease (AZAP)

Sleep Apnea in Early to Mid-Stage Alzheimer's Disease: What Impact of Treatment on the Cognitive Functions of Elderly Patients With Memory Loss?

Obstructive sleep apnea (OSA) is much more common in the elderly than in the young; the latest studies show prevalence between 45% and 62% in individuals over 60. It is even higher in patients with dementia such as Alzheimer patients.

Several trials in elderly patients showed modified cognitive functions, particularly executive and attentional functions, in patients with respiratory sleep disorder. However the benefit of CPAP (Continuous Positive Airway Pressure) ventilation for Alzheimer patients is still controversial, as there are few studies documenting its effects on dementia patients' cognitive abilities, and clinicians appear reluctant to prescribe this type of treatment.

The investigators must keep in mind that Alzheimer patients suffer significant sleep disorders; advanced- stage patients spend 40% of the night awake and are drowsy a large part of the day. In dementia patients, sleep disorder is a major cause of hospitalization and institutionalization. The prevalence of obstructive sleep apnea (OSA) in this population is estimated at over 50%, and appears to be higher the more advanced the dementia. Trials on obstructive sleep apnea syndromes in Alzheimer patients show significatively improved scores on the apnea-hypopnea index (AHI), as well as satisfactory treatment tolerance. However, any impact on cognitive abilities has yet to be demonstrated.

In addition, cardiovascular pathologies such as arterial hypertension, cardiac arrhythmias, and strokes are strongly correlated to OSA. In light of its consequences on morbidity and mortality, OSA should be considered a public health issue.

In this context, the investigators wish to address the impact of CPAP treatment implementation on the cognitive parameters of patients diagnosed with OSA, particularly on their executive functions. This should provide evidence for mid-term assessment of the benefits of CPAP in caring for elderly patients with dementia.

In light of the prevalence of obstructive sleep pathologies in elderly patients reported in various studies and of the potential impact of CPAP treatment on cognitive abilities, the investigators propose a study to evaluate the impact of OSA treatment on elderly Alzheimer patients' cognitive abilities, particularly on their executive functions.

Executive functions are a rather heterogenous group of high-level cognitive processes which enable individuals to adopt a flexible, context-appropriate behavior. They also include planning abilities, working memory, cognitive control, abstract thought, rule learning, selective attention, motor response selection, etc... Executive functions are mainly associated to the functioning of the brain's frontal lobes, although subcortical structures also play a role. When the executive functions are affected by disease, daily life is significantly impeded as the individual becomes unable to perform complex tasks or regulate his/her behavior. Many tests can help evaluate these functions in dementia patients. A number of "ecological" tests, such as the zoo map test from the Behavioural Assessment of the Dysexecutive Syndrome (BADS) arsenal, are quite relevant for evaluating executive functions.

This project aims to improve the daily life of Alzheimer patients with sleep apnea by improving their executive cognitive functions through CPAP treatment.

According to the Paquid's trial, there are 12,400 Alzheimer patients in the French Loire department. [27] The study population will therefore be recruited in the "La Charité" center of CHU Saint-Etienne. The target population is older individuals (≥ 65) suffering from cognitive disorders similar to Alzheimer's disease.

OSA will be diagnosed based on polysomnography, on an outpatient basis. Apnea patients will receive CPAP treatment for 4 months, which is the minimum duration required to implement and accept treatment, and to measure its impact on patients' neurocognitive abilities.

Study Overview

• Status: Terminated
• Conditions: Alzheimer Disease; Early Onset Alzheimer Disease; Obstructive Sleep Apnea Syndromes
• Intervention / Treatment: Device: CPAP Treatment; Device: No treatment

Detailed Description

This study's originality lies in that the target population is elderly and has been diagnosed with both Alzheimer's disease and sleep apnea, and in that it focuses on the impact of treatment on these patient's cognitive abilities, particularly on their executive abilities.We aim to provide practitioners with evidence-based arguments for screening and treating sleep apnea in dementia patients in order to care for these patients, whose treatment options are often scarce.

• Study Type: Observational
• Enrollment (Actual): 22

Contacts and Locations

Study Locations

• France
  • Saint-etienne, France, 42000
    • CHU de Saint-Etienne

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 63 years and older (Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

Elderly patients with a early or mid-Stage Alzheimer's disease with or without SAOS.

Description

Inclusion Criteria:

• Diagnosis of Alzheimer-type dementia confirmed by the study's memory specialist.
• MMS comprised between 20 and 28 (inclusive)
• One main caregiver with full mental capacity, living under the same roof, present at all medical visits
• Patient covered by compulsory health insurance
• Patient signed the informed consent form

Exclusion Criteria:

• Prior diagnosis of sleep apnea or patients already benefitting from respiratory assistance equipment- History of COPD (Chronic Obstructive Pulmonary Disease), treated with bronchodilators or corticoids
• Patients with severe heart failure (stages III and IV of the NYHA Functional Classification)
• Patients with a recent history of stroke or myocardial infarction (within the last three months)
• Recently initiated or modified anticholinergic treatment (within the last two months)
• Patients under guardianship
• Behavioral disorders (pacing, agitation)
• Patients with severe dementia
• Patient with potentially low tolerance to treatment (latex allergies, claustrophobia, prior CPAP treatment which was badly tolerated)
• Serious bullous lung disease
• Pneumothorax
• Arterial hypotension
• Dehydration
• Cerebrospinal fluid effusion, recent concussion, or cranial surgery

Study Plan

How is the study designed?

Design Details

• Observational Models: Cohort
• Time Perspectives: Prospective

Number of groups / cohorts

2

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
OSAS +; Patient with obstructive sleep apnea syndrome (OSAS)detected at the inclusion visit by a polysomnography	Device: CPAP Treatment; Patients with obstructive sleep apnea syndrome will be treated by Continuous Positive Airway Pressure (CPAP) at home during all 4 months all nights.; Other Names: The CPAP devices used are :; PPC ISLEEP 20 (Breas); PPC S8 AUTOSET SPIRIT II AUTO (Resmed); AUTOSET CS2 (Resmed); REMSTAR AUTO M.SERIES (Respironics); REMSTAR PRO M?SERIES (Respironics); PPC SYSTEM ONE AUTO A FLEX (Respironics); PPC SOMNOSMART 2 (Weinmann)
OSAS -; Patient without obstructive sleep apnea syndrome (OSAS)detected at the inclusion visit by a polysomnography	Device: No treatment; no treatment

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Impact of the CPAP treatment on cognitive functions	BADS zoo map scores : subjects are tested in two experimental settings, formulation and execution. The total execution time is the time taken to perform the task assigned in both conditions; the error score measures mistakes made during the test.	At 4 Months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Rate of apnea/hypopnea events per hour (AHI/h)	This secondary outcome measure is only for the treated group by CPAP.	Each month from Day 1 to Month 4
Impact of CPAP treatment on neuropsychological evaluation parameters	This impact is measured by theses following neuropsychological tests : MMS, clock drawing test, five-word test, Benton Visual Retention Test, Similarities Test (WAIS-R subtest), Coding test (WAIS-III subtest), digit and visual span tasks (forward and backward) from WAIS III, alphabetical and categorical verbal fluency tasks, part A and B of the Trail Making Test, and Stroop test. The consideration of these tests separately has no interest. The sum of these tests is important.	At 4 months
Impact of the CPAP treatment on Quality of Life	It measured by the QOL-AD questionnaire	At 4 months

Collaborators and Investigators

• Sponsor: Centre Hospitalier Universitaire de Saint Etienne
• Collaborators: Association Lyonnaise de Logistique Posthospitalière
• Investigators: Principal Investigator: Emilie ACHOUR, MD, CHU de Saint-Etienne

Study record dates

Study Major Dates

• Study Start: December 1, 2010
• Primary Completion (Actual): June 1, 2014
• Study Completion (Actual): June 1, 2014

Study Registration Dates

• First Submitted: July 20, 2011
• First Submitted That Met QC Criteria: July 21, 2011
• First Posted (Estimate): July 22, 2011

Study Record Updates

• Last Update Posted (Estimate): August 11, 2016
• Last Update Submitted That Met QC Criteria: August 9, 2016
• Last Verified: August 1, 2016

More Information

Terms related to this study

• Keywords: Alzheimer Disease; Sleep Apnea Syndromes; Cognitive functions; Early Onset Alzheimer Disease; Obstructive Sleep Apnea Syndromes; Continuous Positive Airway Pressure (CPAP) treatment
• Additional Relevant MeSH Terms: Mental Disorders; Pathologic Processes; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Respiratory Tract Diseases; Respiration Disorders; Sleep Disorders, Intrinsic; Dyssomnias; Sleep Wake Disorders; Neurocognitive Disorders; Disease; Neurodegenerative Diseases; Signs and Symptoms, Respiratory; Dementia; Tauopathies; Sleep Apnea Syndromes; Sleep Apnea, Obstructive; Syndrome; Apnea; Alzheimer Disease
• Other Study ID Numbers: 1002050; 2010-A01003-36 (Other Identifier: AFFSAPS)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No